4D Molecular Therapeutics Inc (FDMT) Live Share Price, Invest From India

4D Molecular Therapeutics Inc Stock Performance

as on May 8, 2026 at 6:59 am IST

Day's Low
Day's High
$9.80
Day's Price Range
$10.35
$9.94
1.41%
Downside
4.12%
Upside
52 Week's Low
52 Week's High
$3.00
52-Week Price Range
$12.34
$9.94
69.82%
Downside
24.14%
Upside

4D Molecular Therapeutics Inc share price movements today

Previous Close: $10.42
Open: $10.33
Volume: 793.1K
Day's Low - High: $9.80 - $10.35
52 Week Low - High: $3.00 - $12.34

4D Molecular Therapeutics Inc Historical Returns

1 Month Return: + 1.76 %
3 Month Return: + 15.91 %
1 Year Return: + 234.51 %
3 Year Return: -38.49 %
5 Year Return: -68.23 %

4D Molecular Therapeutics Inc Stock Fundamentals & Key Indicators

Check 4D Molecular Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$507.6M

EPS (TTM)

-3.8256

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-151.7M

Revenue (TTM)

85.2M

Profit Margin

-164.43%

Return On Equity TTM

-27.57%

4D Molecular Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of 4D Molecular Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
4D Molecular Therapeutics Inc	BUY	$507.6M	-68.23%	NA	-164.43%
Alnylam Pharmaceuticals Inc	BUY	$40.5B	130.77%	76.32	12.55%
BeiGene, Ltd.	NA	$32.5B	NA	70.89	5.37%
Vertex Pharmaceuticals Inc	BUY	$108.5B	98.9%	25.38	35.51%
Regeneron Pharmaceuticals Inc	BUY	$75.6B	45.15%	17.6	29.65%

Stock Returns calculator for 4D Molecular Therapeutics Inc Stock including INR - Dollar returns

The 4D Molecular Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

4D Molecular Therapeutics Inc investment value today

Current value as on today

₹3,54,383

Returns

₹2,54,383

(+254.38%)

Returns from 4D Molecular Therapeutics Inc Stock

₹2,18,590 (+218.59%)

Dollar Impact

₹35,794 (+35.79%)

Analyst Recommendation on 4D Molecular Therapeutics Inc Stock

Based on 17 analysts

BUY

94.12%

Buy

5.88%

Hold

0.00%

Sell

Based on 17 analysts, 94.12% of analysts recommend a 'BUY' rating for 4D Molecular Therapeutics Inc. Average target price of $28.78

4D Molecular Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on 4D Molecular Therapeutics Inc.

What analysts predicted

65.46%UPSIDE

Target Price

$28.78

Current Price

$9.94

Analyzed by

17 Analysts

Target

$28.78

4D Molecular Therapeutics Inc target price $28.78, a slight upside of 65.46% compared to current price of $9.94. According to 17 analysts rating.

Indian Investors' Interest in 4D Molecular Therapeutics Inc Stock

Search interest for 4D Molecular Therapeutics Inc Stock has increased by 11% in the last 30 days, reflecting an upward trend in search activity.

Time period: April 8, 2026 to May 8, 2026

Change:11% versus previous 30 day period

4D Molecular Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	20	0	0	0	0	0	0	0	0	85
Gross Profit	-4	-26	-27	-31	0	-1	0	-47	-47	83
Operating Income	-13	-36	-38	-42	-51	-56	-53	-59	-61	14
EBITDA	-12	-35	-36	-41	-49	-61	-51	-58	-55	6
Interest Expense	-	1	-	-	-	-	-	-	-	-
Depreciation	1	1	1	1	1	1	1	1	2	1
Income Before Tax	-10	-32	-32	-34	-43	-49	-47	-54	-56	19
Income Tax Expense	-3	6	0	-	-	0	-	-	-	-
Net Income	-10	-32	-32	-34	-43	-49	-47	-54	-56	19
Net Profit Margin	-50.76%	169910.53%	-115717.86%	-699060.00%	-1461433.33%	-4967100.00%	-342657.14%	-364386.67%	-63195.56%	22.80%

4D Molecular Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	5	14	6	13	18	3	20	0	85
Gross Profit	-7	-4	-31	-39	18	3	-76	0	77
Operating Income	-11	-10	-50	-56	-71	-110	-112	-187	-159
EBITDA	-10	-9	-44	-55	-68	-106	-108	-181	-151
Interest Expense	-	-	-	0	3	6	-	-	-
Depreciation	0	0	1	1	3	3	5	6	7
Income Before Tax	-11	-9	-49	-56	-71	-107	-100	-160	-140
Income Tax Expense	0	0	3	0	-3	-6	5	-	-
Net Income	-11	-9	-49	-56	-68	-101	-100	-160	-140
Net Profit Margin	-193.83%	-67.59%	-705.78%	-416.49%	-378.63%	-3230.30%	-486.59%	-434778.38%	-164.43%

4D Molecular Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-32	-32	-34	-43	-49	-47	-54	-56	19
Operating Cash Flow	-24	-29	-30	-29	-45	-47	-43	-46	28
Investing Cash Flow	-6	-263	-73	27	7	31	-13	17	-128
Financing Cash Flow	4	318	17	0	0	-	0	0	111
Change in Cash	-26	26	-86	-1	-38	-15	-63	-28	11

4D Molecular Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-9	-49	-56	-71	-107	-100	-160	-140
Operating Cash Flow	-16	-36	-50	-69	-86	-75	-134	-109
Investing Cash Flow	0	-3	-1	-172	-17	115	-302	-92
Financing Cash Flow	84	-2	278	118	3	156	337	112
Change in Cash	67	-42	227	-123	-100	196	-99	-89

Global Institutional Holdings in 4D Molecular Therapeutics Inc

Funds	Holdings
Vanguard Group Inc	5.86%
Susquehanna International Group, LLP	0.26%
The Goldman Sachs Group Inc	8.43%
State Street Corp	2.06%
State Street Corp	5.27%

See all

Insights on 4D Molecular Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, FDMT has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 5 quarters, 1.0K → 85.09M (in $), with an average increase of 70.7% per quarter
POSITIVE IMPACT
Price Rise
In the last 7 days, FDMT stock has moved up by 14.6%
POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -56.87M → 19.39M (in $), with an average increase of 393.2% per quarter
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 23.4% return, outperforming this stock by 60.3%

About 4D Molecular Therapeutics Inc

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.

Organisation	4D Molecular Therapeutics Inc
Headquarters	5858 Horton Street, EmeryVille, CA, United States, 94608
Industry	Biotechnology
CEO	Dr. David H. Kirn M.D.
E-voting on shares	Click here to vote

Key Management of 4D Molecular Therapeutics Inc

Name	Title
Mr. Kristian Humer M.B.A.	CFO and Principal Financial & Accounting Officer
Julian Pei	Head of Investor Relations & Corporate Finance
Dr. Katy Barglow Ph.D.	Chief Technical Officer
Dr. Scott P. Bizily J.D., Ph.D.	Chief Legal Officer & Corporate Secretary
Dr. An Song Ph.D.	Chief Translational Medicine Advisor
Dr. John F. Milligan Ph.D.	Executive Chairman
Dr. David H. Kirn M.D.	Co-Founder, President, CEO & Director
Dr. Fariborz Kamal Ph.D.	Chief Technical Advisor
Ms. Theresa Janke	Co-Founder & Chief of Staff
Dr. Noriyuki Kasahara M.D., Ph.D.	Chief Scientific Advisor & Member of Scientific Advisory Board

FAQs

What is 4D Molecular Therapeutics Inc share price today?

4D Molecular Therapeutics Inc share price today is $9.94 as on May 8, 2026 at 1:29 am IST at the close of the market. 4D Molecular Therapeutics Inc share today touched a day high of $10.35 and a low of $9.8.

What is the 52 week high and 52 week low for 4D Molecular Therapeutics Inc share?

4D Molecular Therapeutics Inc share touched a 52 week high of $12.34 on October 28, 2025 and a 52 week low of $3 on May 9, 2025. 4D Molecular Therapeutics Inc stock price today i.e. May 8, 2026 at 1:29 am IST is closed at $9.94,which is 19.45% down from its 52 week high and 231.33% up from its 52 week low.

What is 4D Molecular Therapeutics Inc's market capitalisation today?

4D Molecular Therapeutics Inc market capitalisation is $0.00T as on May 8, 2026 at 1:29 am IST.

How to invest in 4D Molecular Therapeutics Inc Stock (FDMT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for 4D Molecular Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in 4D Molecular Therapeutics Inc Shares that will get you 0.1509 shares as per 4D Molecular Therapeutics Inc share price of $9.94 per share as on May 8, 2026 at 1:29 am IST.

What is the minimum amount required to buy 4D Molecular Therapeutics Inc Stock (FDMT) from India?

Indian investors can start investing in 4D Molecular Therapeutics Inc (FDMT) shares with as little as ₹94.24 or $1 (as of May 8, 2026 at 6:41 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹942.40 in 4D Molecular Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on May 8, 2026 at 6:41 am IST). Based on 4D Molecular Therapeutics Inc share’s latest price of $9.94 as on May 8, 2026 at 1:29 am IST, you will get 1.0060 shares of 4D Molecular Therapeutics Inc. Learn more about fractional shares .

What are the returns that 4D Molecular Therapeutics Inc has given to Indian investors in the last 5 years?

4D Molecular Therapeutics Inc stock has given -68.23% share price returns and 29.81% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?